Lokelma for RAAS Maximisation in CKD & Heart Failure.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT05004363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
St George's, University of London (from the registry)
Registry
  • NCT NCT05004363
  • EudraCT 2020-002946-18
Other papers using this trial's data
  • Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial Nature communications, 2026-10-14 DOI, PubMed 43015282, PMC13754891 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05004363. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-19 (actual); primary completion 2024-07-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Acronym
LIFT
Condition
Chronic Kidney Diseases
Condition
Hyperkalemia
Condition
ACE Inhibitor Induced Hyperkalaemia
Condition
Mineralocorticoid Resistant Hyperkalemia
Intervention (Drug)
Lokelma Oral Product
Lead sponsor
St George's, University of London (class: other)

Record details

Record id
cardio:ct-nct05004363
Content hash
6fbf3f9ccd7a573d89a556d00e1098d9ed61f50dbf08702f9557902bf509d4ce